Skip to content
#graph neural networks Review Open access

Artificial intelligence-enabled cross-scale integration of traditional Chinese medicine and biomedicine for sepsis: from mechanisms to delivery

Sep 2026 · Frontiers in Pharmacology · Vol 17 · 0 citations · 53 references
Medicine

TL;DR

A conceptual framework for an integrated “target recognition–drug matching–carrier design–subtype adaptation” decision model is proposed, which may inform the matching of combined biomedical and botanical drug regimens with nanodelivery systems based on patient molecular subtypes.

Abstract

Sepsis is an organ dysfunction caused by a dysregulated host immune response to infection. Its pronounced heterogeneity and cross-scale pathological disturbances have resulted in poorly defined core therapeutic targets and inefficient drug delivery. Artificial intelligence, with its capacity for high-dimensional data integration, can serve as a data-integrative and hypothesis-generating tool, offering new avenues for exploring potential solutions to the aforementioned bottlenecks. This review summarizes recent advances in AI-driven multi-omics-based mechanistic dissection, the use of nanodelivery systems to optimize the in vivo behavior of both biomedical and botanical drugs, and AI-assisted nanocarrier design. At the mechanistic level, AI integrates multi-omics data with graph neural networks to provide computational clues for precise molecular subtyping and the identification of potential candidate targets such as S100A8/A9 and TREM-1. At the delivery level, nanocarriers help overcome the off-target toxicity of biomedical agents and the poor bioavailability of botanical drugs, while lesion acidification, high ROS levels, high MMP expression, and the EPR effect provide a biological basis for stimuli-responsive delivery. At the integration level, AI translates target information and microenvironmental parameters into carrier design parameters, offering computational support for material screening and response threshold optimization. A conceptual framework for an integrated “target recognition–drug matching–carrier design–subtype adaptation” decision model is proposed, which may inform the matching of combined biomedical and botanical drug regimens with nanodelivery systems based on patient molecular subtypes. This cross-scale integration framework may offer a reference direction for research on sepsis and other heterogeneous inflammatory diseases.

Read PDF

Similar papers

Review Open access Sep 2026

Insights into the use of artificial intelligence in the drug discovery and delivery of nanosystems for the treatment of infectious diseases and neoplasms.

The convergence of AI and nanotechnology is revolutionizing healthcare by providing more accurate diagnostics, tailored treatments, and improved safety evaluations, and AI-driven models enhance drug discovery, optimize delivery systems, and strengthen toxicological assessments.

Vinicius Martinho Borges Cardoso, Camila Rodrigues Santana, Giovanna Justino Momente et al. · 0 citations
Review Open access Sep 2026

Artificial Intelligence Enabled Intelligent Nanoparticle for Precision Therapeutics in Persistent Post-Covid Syndrome: A Next Generation Translational Medicine Perspective

Persistent Post-COVID Syndrome (PPCS), commonly known as Long COVID, has emerged as a major global health challenge affecting millions of individuals after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Its heterogeneous clinical manifestations, prolonged symptom duration, and complex pathophys...

S. S, Genesis Mgp, Gopukumar · 0 citations
Review Sep 2026

Precision Drug Discovery in the Era of Artificial Intelligence: A Critical Review.

A paradigm shift toward autonomous scientific agents capable of causal reasoning and end-to-end experimental guidance is highlighted, and persistent challenges are discussed, including data bias, limited interpretability, and in silico-to-wet lab translation.

Meng Liu, Jia-Cheng Xiong, Ming-Yue Zheng · 1 citation
Review Open access Aug 2026

Artificial Intelligence Integration With Nanotechnology for Cancer Therapy

This review discusses AI‐guided strategies for material design, targeting, payload optimization, and in vivo delivery, with particular attention to protein corona‐mediated biological identity, microenvironment‐responsive activation, and biodistribution modeling.

Sheng-Bin Liu, Zhi Liu, Hai-Xing Shi et al. · 0 citations
Review Sep 2026

Harnessing Artificial Intelligence to Predict and Overcome Drug Resistance in Breast Cancer: A Translational Approach.

This review discusses how AI can accelerate computational drug discovery, virtual screening (VS), and the repurposing of already-approved medications, and it can also optimize combination therapies through computational simulation.

D. Bhagwat, Sonali A. Chikhalwale, S. Mali et al. · 0 citations
Review Open access Sep 2026

APPLICATIONS OF DATA ANALYSIS AND ARTIFICIAL INTELLIGENCE AGENTS IN NOVEL DRUG DISCOVERY: A CRITICAL LITERATURE REVIEW

This evidence-based literature review critically examines the evolution and application of computational technologies across the pharmaceutical pipeline, ranging from early expert systems like DENDRAL, computer-aided drug design (CADD), and quantitative structure-activity relationship (QSAR) modeling to AlphaFold 3 bio...

Leonardo Mairene Muniz · 0 citations

Related blog posts

Microsoft Research Blog Jul 13, 2026

Verifying Rust cryptography in SymCrypt, from standards to code

Cryptographic code supports vital protections in modern computing systems. Learn how a new method helps verify code as developers write it while preserving speed and adaptability as it gets implemented and evolves. The post Verifying Rust cryptography in SymCrypt, from standards to code appeared first on Microsoft Research.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.